A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

A newly engineered antibody transport vehicle targeting the transferrin receptor enables enhanced delivery of anti-amyloid ...

Why does the brain of some people stay sharp into their 80s and beyond? An expert explains what 25 years of exploring the ...